Roshchino

Researchers are evaluating the efficacy and safety of cariprazine in treating adolescents aged 13 to 17 years with schizophrenia. This Phase 3 study compares cariprazine to a placebo to understand its effects on this population. Participants must have a confirmed diagnosis of schizophrenia based on DSM-5 criteria and meet specific symptom severity requirements. Participants receive either cariprazine or matching placebo capsules once daily by mouth for 6 weeks in a randomized, double-blind, parallel-group design. The study is conducted across multiple international centers to ensure diverse participation and data collection. Throughout the 6-week study, researchers assess changes in schizophrenia symptoms using the PANSS total score from baseline to Week 6. Safety and tolerability are also monitored closely. Participants will undergo clinical evaluations and symptom scoring to track progress and response to treatment during the study period.

Researchers are evaluating the effectiveness and safety of the drug DMB-I (Latrepirdine) in treating adults with Alzheimer type dementia. The study aims to determine whether DMB-I improves cognitive functions compared to a placebo, understand any medical problems participants may experience while taking DMB-I, and assess the long-term safety and effectiveness of DMB-I. This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial conducted in approximately 15 sites in the Russian Federation. The study includes two 26-week stages. In Stage 1, patients are assigned to one of three groups: Group 1 receives DMB-I plus Akatinol Memantine®, Group 2 receives placebo plus Akatinol Memantine®, and Group 3 receives DMB-I alone. DMB-I is given as 10 mg doses, two tablets three times daily; Memantine is given once daily at 20 mg. Stage 1 is double-blind for DMB-I and placebo, while Memantine is not blinded. After Stage 1, patients enter an open-label Stage 2 for another 26 weeks: Group 1 continues their therapy unchanged, Group 2 switches from placebo to DMB-I while continuing Memantine, and Group 3 continues DMB-I monotherapy. Participants will visit the clinic 13 times for checkups and tests over approximately 56 weeks, including up to 2 weeks of screening, 52 weeks of treatment, and a 2-week follow-up. They will keep diaries of their symptoms, and researchers will assess cognitive function changes using the ADAS-Cog scale, comparing scores at Week 26 to baseline. Safety and long-term effects of DMB-I will be monitored throughout the study.